Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03742037 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
A Phase 2 study, sponsored by Viatris Innovation.
- Completed
- Registry status
- Phase 2
- Development phase
- 427
- Enrollment target
NCT03742037: Completed Phase 2 study, sponsored by Viatris Innovation.
NCT03742037 is a Phase 2 study that has completed, run by Viatris Innovation. The registered enrollment target is 427 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (221% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03742037, a Phase 2 study, has completed, sponsored by Viatris Innovation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 427 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with systemic lupus erythematosus (SLE).
Primary Outcome
The primary endpoint is the absolute change from baseline in the modified Systemic Lupus Erythematosus Activity Index 2000 (mSLEDAI-2K) score. The SLEDAI-2K is a cumulative index of lupus disease activity scored by the physician. It is calculated from 24 individual descriptors across 9 organ systems, with weighted scores of 2-8, and measures disease activity within the last 10 days. 0 points indicates inactive disease, and 105 points is the maximum possible score. In this study the SLEDAI-2K was
Interventions
- DRUG Placebo
- DRUG Cenerimod 0.5 mg
- DRUG Cenerimod 1 mg
- DRUG Cenerimod 2 mg
- DRUG Cenerimod 4 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 427 participants |
| Start Date | 2018-12-21 |
| Est. Completion | 2022-08-25 |
| Phase | Phase 2 |
What the finished NCT03742037 record still lists
NCT03742037 is an interventional study that assigns participants to a tested intervention. The registered 427 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (221% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03742037 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03742037 about?
NCT03742037 is a clinical study titled "Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus". The purpose of the study is to assess the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with systemic lupus erythematosus (SLE).
What is the current status of trial NCT03742037?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 427 participants. The study started on 2018-12-21. Estimated completion is 2022-08-25.
What interventions are being tested in trial NCT03742037?
The interventions under investigation include: Placebo (DRUG), Cenerimod 0.5 mg (DRUG), Cenerimod 1 mg (DRUG), Cenerimod 2 mg (DRUG), Cenerimod 4 mg (DRUG).
Who is sponsoring clinical trial NCT03742037?
This trial is sponsored by Viatris Innovation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03742037's enrollment target sits among peer trials
427 91st of 2000 higher than 1,910 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05566431 · 428 participants · NA
Benchmark Evidence Led by Latin America: Trial of Intracranial Pressure - Pediatrics
- NCT05646316 · 428 participants · Phase 3
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
- NCT05797610 · 428 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- NCT06073626 · 428 participants · NA
Addressing Genomic Disparities in Cancer Survivors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI